The increase in IGFBP-3 concentration, which could be a result of an inflammatory response to brain degeneration [105], may reduce bioavailable IGF-1 in the AD brain, further reducing the amount of bioavailable IGF-1. This evidence concerns the gene IGF1 and Alzheimer disease.